[HTML][HTML] A recombinant vesicular stomatitis virus Ebola vaccine
JA Regules, JH Beigel, KM Paolino… - … England Journal of …, 2017 - Mass Medical Soc
Background The worst Ebola virus disease (EVD) outbreak in history has resulted in more
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …
Fractional third and fourth dose of RTS, S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study
JA Regules, SB Cicatelli, JW Bennett… - The Journal of …, 2016 - academic.oup.com
Background. Three full doses of RTS,S/AS01 malaria vaccine provides partial protection
against controlled human malaria parasite infection (CHMI) and natural exposure. Immunization …
against controlled human malaria parasite infection (CHMI) and natural exposure. Immunization …
Targeted Intranasal Mupirocin To Prevent Colonization and Infection by Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Soldiers: a …
…, KA Davis, JS Hawley, JA Regules… - Antimicrobial agents …, 2007 - Am Soc Microbiol
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is an emerging
pathogen that primarily manifests as uncomplicated skin and soft tissue infections. We …
pathogen that primarily manifests as uncomplicated skin and soft tissue infections. We …
The RTS, S vaccine candidate for malaria
JA Regules, JF Cummings… - Expert review of …, 2011 - Taylor & Francis
Malaria continues to be a worldwide leading cause of morbidity and mortality, and the
development of an effective malaria vaccine remains a research imperative. Of the multiple …
development of an effective malaria vaccine remains a research imperative. Of the multiple …
[HTML][HTML] Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
…, KM Paolino, R Phillips, NC Waters, JA Regules… - Scientific reports, 2016 - nature.com
The most recent Zaire Ebolavirus (ZEBOV) outbreak was the largest and most widespread in
recorded history, emphasizing the need for an effective vaccine. Here, we analyzed human …
recorded history, emphasizing the need for an effective vaccine. Here, we analyzed human …
[HTML][HTML] The biological function of antibodies induced by the RTS, S/AS01 malaria vaccine candidate is determined by their fine specificity
S Chaudhury, CF Ockenhouse, JA Regules, S Dutta… - Malaria Journal, 2016 - Springer
Background Recent vaccine studies have shown that the magnitude of an antibody response
is often insufficient to explain efficacy, suggesting that characteristics regarding the quality …
is often insufficient to explain efficacy, suggesting that characteristics regarding the quality …
[HTML][HTML] Delayed fractional dose regimen of the RTS, S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis
S Chaudhury, JA Regules, CA Darko, S Dutta… - Scientific Reports, 2017 - nature.com
A recent study of the RTS,S malaria vaccine, which is based on the circumsporozoite protein
(CSP), demonstrated an increase in efficacy from 50–60% to 80% when using a delayed …
(CSP), demonstrated an increase in efficacy from 50–60% to 80% when using a delayed …
[HTML][HTML] A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum
…, L Yang, W Volkmuth, E Locke, JA Regules… - PLoS …, 2022 - journals.plos.org
Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS,S/AS01 is the first, and to date, the only vaccine that has …
Plasmodium falciparum (Pf). RTS,S/AS01 is the first, and to date, the only vaccine that has …
A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive …
JE Moon, C Ockenhouse, JA Regules… - The Journal of …, 2020 - academic.oup.com
Background A previous RTS,S/AS01 B vaccine challenge trial demonstrated that a 3-dose (0-1-7–month)
regimen with a fractional third dose can produce high vaccine efficacy (VE) in …
regimen with a fractional third dose can produce high vaccine efficacy (VE) in …
[HTML][HTML] Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum
…, WB Harrison, X Zou, Z Beck, GR Matyas, JA Regules… - npj Vaccines, 2022 - nature.com
The Circumsporozoite Protein (CSP) of Plasmodium falciparum contains an N-terminal region,
a conserved Region I (RI), a junctional region, 25–42 copies of major (NPNA) and minor …
a conserved Region I (RI), a junctional region, 25–42 copies of major (NPNA) and minor …
